Tensions in antibiotic prescribing
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
BACKGROUND: To reduce the prevalence of antibioticresistant bacteria in the community, physicians must optimize their use of antibiotics. However, optimal use from the perspective of the community (reserving newer agents for future use) is not always consistent with optimal use from the perspective of the individual patient (prescribing newer, broader agents).
OBJECTIVES: To identify preferred patterns of antibiotic prescribing for patients with community-acquired pneumonia (CAP), measure explicit attitudes toward antibiotics and antibiotic resistance, and determine the relationship between these prescribing patterns and attitudes.
DESIGN: Cross-sectional anonymous mail survey.
PARTICIPANTS: National random sample of 400 generalist physicians (general internal medicine and family practice) and 429 infectious diseases specialists.
MEASUREMENTS: Rank ordering of antibiotic preferences for a hypothetical outpatient with CAP and reasons for antibiotic selection. Endorsement of attitudes regarding antibiotic prescribing decisions and resistance.
RESULTS: Both generalists and infectious diseases specialists were more likely to prefer newer, broader drugs for the treatment of CAP compared to older agents still recommended by national guidelines. Physicians rated the issue of contributing to antibiotic resistance lowest among 7 determinants of their choices.
CONCLUSIONS: Despite national guidelines and increasing public awareness, the public health concern of contributing to the problem of antibiotic resistance does not exert a strong impact on physician prescribing decisions for CAP. Future efforts to optimize antibiotic prescribing decisions will need to consider options for increasing the impact of public health issues on the patient-oriented decisions of individual physicians.
- Levy SB. Confronting multidrug resistance. A role for each of us. JAMA. 1993;269:1840–2. CrossRef
- Cohen ML. Epidemiology of drug resistance: implications for a post-antimicrobial era. Science. 1992;257:1050–5. CrossRef
- Bartlett JG, Dowell SF, Mandell LA, File TM Jr, Musher DM, Fine MJ. Practice guidelines for the management of communityacquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis. 2000;31:347–82. CrossRef
- Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis. 1999;29:745–58.
- Schwartz B, Bell DM, Hughes JM. Preventing the emergence of antimicrobial resistance. A call for action by clinicians, public health officials, and patients. JAMA. 1997;278:944–5. CrossRef
- Schwartz B. Preventing the spread of antimicrobial resistance among bacterial respiratory pathogens in industrialized countries: the case for judicious antimicrobial use. Clin Infect Dis. 1999;28:211–3.
- Gonzales R, Bartlett JG, Besser RE, et al. Principles of appropriate antibiotic use for treatment of acute respiratory tract infections in adults: background, specific aims, and methods. Ann Intern Med. 2001;134:479–86.
- Low DE, Scheld WM. Strategies for stemming the tide of antimicrobial resistance. [editorial; comment]. JAMA. 1998:279:394–5. CrossRef
- Seppala H, Klaukka T, Vuopio-Varkila J, et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. N Engl J Med. 1997;337:441–6. CrossRef
- Arason VA, Kristinsson KG, Sigurdsson JA, Stefansdottir G, Molstad S, Gudmundsson S. Do antimicrobials increase the carriage rate of penicillin-resistant pneumococci in children? Cross sectional prevalence study. BMJ. 1996;313:387–91.
- Chen DK, McGeer A, de Azavedo JC, Low DE. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. N Engl J Med. 1999;341:233–9. CrossRef
- Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 2001;163:1730–54.
- Hooper DC. Expanding uses of fluoroquinolones: opportunities and challenges. Ann Intern Med. 1998;129:908–10.
- Heffelfinger JD, Dowell SF, Jorgensen JH, et al. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med. 2000;160:1399–408. CrossRef
- Whitney CG, Farley MM, Hadler J, et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med. 2000;343:1917–24. CrossRef
- Bartlett JG, Breiman RF, Mandell LA, File TM Jr. Community-acquired pneumonia in adults: guidelines for management. The Infectious Diseases Society of America. Clin Infect Dis. 1998;26:811–38.
- Niederman MS, Bass JB Jr., Campbell GD, et al. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association. Am Rev Respir Dis. 1993;148:1418–26.
- Christakis NA, Asch DA. Medical specialists prefer to withdraw familiar technologies when discontinuing life support. J Gen Intern Med. 1995;10:491–4. CrossRef
- Asch DA, Christakis NA, Ubel PA. Conducting physician mail surveys on a limited budget. A randomized trial comparing $2 bill versus $5 bill incentives. Med Care. 1998;36:95–9. CrossRef
- Allison P, Christakis N. Logit models for sets of ranked items. Sociology Methodol. 1994;24:199–228. CrossRef
- Asch DA, Christakis NA. Why do physicians prefer to withdraw some forms of life support over others? Intrinsic attributes of life-sustaining treatments are associated with physicians’ preferences. Med Care. 1996;34:103–11. CrossRef
- Baquero F. Evolving resistance patterns of Streptococcus pneumoniae: a link with long-acting macrolide consumption? J Chemother. 1999;11:35S-43S.
- Gilbert K, Gleason PP, Singer DE. et al. Variation in antimicrobial use and cost in more than 2,000 patients with community-acquired pneumonia. Am J Med. 1998;104:17–27. CrossRef
- Gleason PP, Kapoor WN, Stone RA, et al. Medical outcomes and antimicrobial costs with the use of the American Thoracic Society guidelines for outpatients with community-acquired pneumonia. JAMA. 1997;278:32–9. CrossRef
- Asch DA, Jedrziewski MK, Christakis NA. Response rates to mail surveys published in medical journals. J Clin Epidemiol. 1997;50:1129–36. CrossRef
- Cummings SM, Savitz LA, Konrad TR. Reported response rates to mailed physician questionnaires. Health Serv Res. 2001;35:1347–55.
- Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group. Clin Infect Dis. 2000;31:383–421. CrossRef
- Shlaes DM, Gerding DN, John JF Jr., et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis. 1997;25:584–99.
- Tensions in antibiotic prescribing
Journal of General Internal Medicine
Volume 17, Issue 2 , pp 87-94
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- drug utilization
- physician’s practice patterns
- drug resistance
- Industry Sectors
- Author Affiliations
- 1. the Philadelphia Veterans Affairs Medical Center, University of Pennsylvania, Philadelphia, Pa
- 2. the Division of General Internal Medicine, Department of Medicine, University of Pennsylvania, Philadelphia, Pa
- 3. the Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pa
- 4. the Center for Education and Research on Therapeutics, University of Pennsylvania, Philadelphia, Pa
- 5. the Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, Pa